Using Blood Proteins to Predict Outcomes in Liver Cancer Patients on Sunitinib
Author Information
Author(s): Harmon Charles S, DePrimo Samuel E, Raymond Eric, Cheng Ann-Lii, Boucher Eveline, Douillard Jean-Yves, Lim Ho Y, Kim Jun S, Lechuga Maria José, Lanzalone Silvana, Lin Xun, Faivre Sandrine
Primary Institution: Pfizer Oncology, La Jolla, CA, USA
Hypothesis
Can circulating proteins related to sunitinib's mechanism of action serve as biomarkers for clinical outcomes in patients with unresectable hepatocellular carcinoma?
Conclusion
High baseline levels of VEGF-C in plasma can predict better clinical outcomes for patients with hepatocellular carcinoma receiving sunitinib.
Supporting Evidence
- Patients with high baseline VEGF-C levels had significantly longer time to tumor progression.
- Baseline VEGF-C levels were an independent predictor of overall survival.
- Changes in plasma protein levels were correlated with clinical outcomes.
Takeaway
Doctors can check certain proteins in the blood to see if a liver cancer treatment will work better for some patients.
Methodology
Patients received sunitinib 50 mg/day for 4 weeks, followed by 2 weeks off, with plasma samples analyzed for specific proteins.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study had a small sample size and was not powered for strong statistical analyses.
Participant Demographics
Predominantly male (92%) with Child-Pugh class A liver function (84%).
Statistical Information
P-Value
0.0029 for baseline VEGF-C levels
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website